Response definition criteria for ELISPOT assays revisited - Test2 - elhamkhani - TriplyDB

Response definition criteria for ELISPOT assays revisited

Response definition criteria for ELISPOT assays revisited

http://www.wikidata.org/entity/Q30495664

about

Microchip platforms for multiplex single-cell functional proteomics with applications to immunology and cancer research Systems Biology Approach for Cancer Vaccine Development and Evaluation Vaccine against autoimmune disease: antigen-specific immunotherapy Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Epitope specific T-cell responses against influenza A in a healthy population.Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry.Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T cell responses The immuno-oncology framework: Enabling a new era of cancer therapy.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring.A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B Cytomegalovirus-specific T-cell reactivity in biliary atresia at the time of diagnosis is associated with deficits in regulatory T cells.Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients.Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.Defining ELISpot cut-offs from unreplicated test and control wells.Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies Identification of immunological biomarkers which may differentiate latent tuberculosis from exposure to environmental nontuberculous mycobacteria in children.

P2860

Q21183961-E5F9EBD1-759E-4D6B-8A2F-ACEC9EFA3501 Q26782580-60230E27-BAE6-4EE0-B8EB-621EA44A5D65 Q27028121-4C195EF3-A80F-4900-AA0D-570EC92D55A0 Q28740321-E9D87DC1-B2A6-4AFC-9FF9-C95FEF09A982 Q28741673-6736329C-3EF5-42A1-84EC-FF7D760A1059 Q28744503-08635602-53D6-4AC0-B9A2-412FD6CD23CB Q30202358-CFC440AD-66A3-47B0-8932-4D1E1991E618 Q30416916-549458DD-7104-4A2A-AD80-918FD135646A Q30528191-ACEBAD82-7151-4DFE-B218-4DF6AA6A9131 Q33737476-B888EB2D-88E3-44FC-8F16-12E2EEA5AB02 Q33923216-73012420-4260-41EC-B232-DE9F48C23B74 Q34047191-B6B2CBD4-A4FA-464E-B48D-94A9B0F0BC3F Q34053837-C1DD4EEF-E113-449D-BB18-E8FCAE100020 Q34284462-E4952F5A-8BD7-435E-81B0-8265C4AF3DD6 Q34333155-B13F1537-B21C-40AF-836E-9812ADFCBB6E Q34530756-A3D45E0A-2998-4C1D-9E35-D43DF58C36A5 Q34593969-F91E4102-DC35-43B7-AA35-806561EF85E0 Q34730713-7E8BD2DF-77AF-4909-A8F6-28508638AEC6 Q34742548-75503931-FDFA-4BCB-83AB-C1BA1B08E9AD Q34764031-E1C38D04-38F0-40E4-BD8B-8EED39A0B471 Q34796892-6FF35DC3-6174-4669-982A-9816DF0EF579 Q34999059-2EB5851F-E0D8-4BB4-91C2-3CAC2754A618 Q35567414-C78BDF72-7B0D-492E-B351-0461463CE593 Q35716201-51976640-D533-4815-B825-5A124EFAD501 Q35824191-F5B2A8C2-B7AF-4350-8AF3-DDDD8789BE61 Q35850475-CF918D55-F736-4B75-AF9D-6F42EC950B05 Q35870141-7B3ECDDC-4B44-4A8B-A90A-D16488BCB5FD Q35919760-28611229-E408-478D-8DF0-8135E2738CFA Q36106412-8C738531-4F55-48FA-B29C-8896BC553F36 Q36158727-D4FADC02-BDFC-41AF-BBF9-3D2A0A17CCDC Q36185518-530E21F1-C337-4585-87D7-699DEA7FB9F1 Q36189261-BF59E8B9-6A98-4621-9CC2-FABF3F5B9390 Q36194843-62225368-E8E8-4A74-92BC-959FE7BDC672 Q36300011-B9AB6DD1-4A63-47CB-AF7D-1A7F5058599E Q36347381-4885B69A-ED5B-4549-9505-B9E5FC2899AE Q36448384-3E586ED2-6CF6-43FC-9B8D-85C348CA6238 Q36821179-71F37B38-2579-4027-9D46-695CB80C4342 Q36852775-552A69B5-74F7-4409-922F-8538DC435A2B Q36880258-CB6EFD1D-A2CC-459E-8531-BEF5A5F9F8D7 Q37545011-0ED456EC-CAAB-4A07-90E3-AF3A9FE5CB69

P2860

Response definition criteria for ELISPOT assays revisited

http://www.wikidata.org/entity/Q30495664

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Response definition criteria for ELISPOT assays revisited

@ast

Response definition criteria for ELISPOT assays revisited

@en

type

label

Response definition criteria for ELISPOT assays revisited

@ast

Response definition criteria for ELISPOT assays revisited

@en

prefLabel

Response definition criteria for ELISPOT assays revisited

@ast

Response definition criteria for ELISPOT assays revisited

@en

P1433

Q30495664-0E91F767-EB48-41F7-A333-3662DAB573B9

P1476

Q30495664-5ED23EDE-C1F8-4CAF-A7AA-1C4D653DAFE1

P2093

Q30495664-0C903280-04A0-4F2F-AE80-917A05270E27

Q30495664-32F79FCF-77D4-4CEB-B7B1-62E5FC1A1AF4

Q30495664-39EA950F-B28D-427D-BEFF-9569DCB689FE

Q30495664-3E8E4900-488B-4D11-8C6C-813CD2CA4864

Q30495664-6025B52B-3950-424B-997E-12A578DCFD95

Q30495664-7019F608-2AC5-4171-99C7-9CC97A9D72D6

Q30495664-A4476B4E-8321-47DE-81CC-1BD1BF23CE13

Q30495664-B1BA3CA2-B29E-4810-BF30-9B0707384023

Q30495664-E6D23E12-3543-449D-AEBF-34E33A0C7649

P2860

Q30495664-0E7C441C-19C0-4CD1-80A0-A1F7BDD0A410

Q30495664-3D86ACF4-86F3-421B-A583-0FA02654661F

Q30495664-4E9F93A3-C8EF-43B0-AE66-1C91742A8BF7

Q30495664-5AD29C9C-B64D-4676-ACAA-8ECD6B9809BF

Q30495664-6F1AAE0C-EE48-4F4D-BB4D-13602BE37DAD

Q30495664-715263F6-8AF2-4824-82E4-DD2EB6363F21

Q30495664-7A84CBE0-D0D5-4397-9D80-A13671C83506

Q30495664-86004880-2A12-4F3E-B671-C005F52D341E

Q30495664-8F4045F6-8CAE-46DA-9FF5-2AB00CF7A977

Q30495664-99F0FE80-A70E-448A-B18B-4F8EE4BCE1E6

P2888

Q30495664-F929E474-6BAB-4D5F-B78A-29B3C2340016

P304

Q30495664-035C2BE8-17B0-487A-8F6B-B9A93B4BD3EF

P31

Q30495664-96919428-8798-4A7A-880F-DC8708E55E93

P356

Q30495664-64AC5910-3BC4-47DE-9206-2E00A9B3A047

P433

Q30495664-834563BD-07C5-4E2F-94ED-4F841A03AEDA

P478

Q30495664-D79720B8-721C-4881-BF99-3E536BA2B428

P50

Q30495664-DFE308CE-E954-4BAF-83F6-AEA9F0870733

P577

Q30495664-CF15959B-C3E1-468B-BE71-14EBD131A7F0

P5875

Q30495664-4D5C59C5-2EFE-4A92-8F8E-8DE470CD8810

P6179

Q30495664-ED1FB98B-2F13-406E-AA84-1D03545EE988

P698

Q30495664-FEA26259-BAF3-4316-8EE8-D579B47E257B

P932

Q30495664-F87BB1DA-19F1-4B92-A01B-C506E6A2CE73

P356

S00262-010-0875-4

P1433

Cancer Immunology, Immunotherapy

P1476

Response definition criteria for ELISPOT assays revisited

@en

P2093

A Mander

http://www.w3.org/2001/XMLSchema#string

C Gouttefangeas

http://www.w3.org/2001/XMLSchema#string

Cedrik M Britten

http://www.w3.org/2001/XMLSchema#string

L Price

http://www.w3.org/2001/XMLSchema#string

M J P Welters

http://www.w3.org/2001/XMLSchema#string

M Löwer

http://www.w3.org/2001/XMLSchema#string

S H van der Burg

http://www.w3.org/2001/XMLSchema#string

S Janetzki

http://www.w3.org/2001/XMLSchema#string

Z Moodie

http://www.w3.org/2001/XMLSchema#string

P2860

More powerful procedures for multiple significance testing

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.

Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

P2888

s00262-010-0875-4

P304

1489-1501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0875-4

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Christian H. Ottensmeier

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44674347

http://www.w3.org/2001/XMLSchema#string

P6179

1039584399

http://www.w3.org/2001/XMLSchema#string

P698

20549207

http://www.w3.org/2001/XMLSchema#string

P932

2909425

http://www.w3.org/2001/XMLSchema#string